|
|
CEO and President |
Paul has extensive experience of global sales, strategic marketing and business development. He was born in 1962 and was appointed as Aerocrine’s CEO in 2007. He was previously Senior Vice President of Commercial & Strategic Development, and a member of the corporate management of Biovitrum AB. He was also Executive Vice President of Global Strategic Marketing at Fresenius Kabi AB, which is part of the German Fresenius AG group, and was Head of Global Sales & Strategic Marketing at Pharmacia, as well as several international executive positions within the Unilever group in Europe.
He is the sole shareholder of Ytterby Holding AS.
Aerocrine shareholding: 20,650.
 |
Director of Scientific & Medical Affairs | Kjell Alving is the Director of Scientific & Medical Affairs and also co-founder of Aerocrine AB. Kjell is a Professor of Respiratory Pharmacology. He was born in 1959 and took up his position in Aerocrine’s management team in 2007. He joined Aerocrine from the Karolinska Institute, where he has been active in preclinical and clinical research for more than 20 years. His research included the discovery that asthmatics have increased NO levels in exhaled air. Kjell is a Board member of Alving & Ersson AB, and was previously a Board member of Nitricare AB. Kjell previously conducted allergy research in the former Pharmacia Diagnostics AB.
Aerocrine shareholding: 139,440 and warrants corresponding to 70,000 shares. |
 |
VP Development & Technical Operations |
Mr Carlson was born in 1953 and has been a member of Aerocrine’s management since 1998. He has over 20 years’ product development and production experience in pharmaceuticals and medical technology. Mats is also a deputy Board member of RegMan AB. He was a Board member of the Swedish Industrial Design Foundation, SEDOC PM AB and the Karolinska Institute’s biotechnology Ph.D. program focusing on industry. His previous experience includes CEO of Pharmacia Chiron Partnership, a consultant for Wenell Management AB, Project Co-ordinator at Pharmacia and Project Manager at Siemens-Elema in product development for intensive care.
Aerocrine shareholding: 3,000 and warrants corresponding to 160,000 shares. |
 |
Chief Financial Officer, |
Michael Colérus has a professional background in Pharmacia & Upjohn where he was Business Controller for several business areas. Michael was born in 1962, and has been Aerocrine’s CFO since 1999.
Aerocrine shareholding: 5,300 and warrants corresponding to 30,000 shares. |
 |
President
Aerocrine Inc. |
Chip Neff has over 20 years experience in global sales, marketing and business development in the medical diagnostic business. He was born in 1962 and was appointed as Aerocrine, Inc. President in February of 2008. He previously worked for Quest Diagnostics Incorporated where he was responsible for North American Sales/Marketing for their HemoCue point-of-care testing business. Before the successful acquisition of HemoCue AB by Quest Diagnostics, he worked for HemoCue AB for 12 years where he held a number of senior management positions. He holds as BS in Economics from Denison University in Ohio. |
 |
International Marketing & Sales Director |
Magnus has been heading our sales and marketing organization in Germany since 2005 and has now also taken on the position as Vice President Global Sales at Aerocrine AB.
Magnus has more than 35 years experience of the European pharmaceutical and dental products industries. He has held various positions in national and international marketing within Dumex AS including serving as the general manager for the German subsidiary and as international marketing director.
For Swedish BIORA he established its operations in Germany, Austria, and Switzerland. In 2000 he joined the US Company Atrix Laboratories Inc. where he served as vice president sales and marketing, responsible for the company’s new European sales and marketing operations.
Aerocrine shareholding: 0 |
|